Skip to main content

Table 5 Significant effects of poly-miRTS on adverse events after chemotherapy of AML patients (Chi square/Fisher’s exact test)

From: Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients

SNP genotypes Total (n) Adverse events   OR (95% CI)
Yes (n, %) No (n)
rs3743527   Myelosuppression    
 CC 63 48 (76.2) 15   1.00 (reference)
 TC 108 85 (78.7) 23 0.703 1.155 (0.51–2.422)
 TT 35 34 (97.1) 1 0.007 10.625 (1.339–84.317)
 TC+TTa 143 119 (83.2) 24 0.236 1.549 (0.749–3.206)
rs212091   Myelosuppression    
 AA 122 107 (87.7) 15   1.00 (reference)
 AG 72 51 (70.8) 21 0.003 0.340 (0.162–0.715)
 GG 12 9 (75.0) 3 0.431 0.421 (0.102–1.729)
 AG+GGa 84 60 (71.4) 24 0.003 0.350 (0.171–0.719)
rs212090   Gastrointestinal reaction    
 TT 135 37 (27.4) 98   1.00 (reference)
 AT 63 29 (46.0) 34 0.010 2.259 (1.211–4.213)
 AA 8 0 (0) 8 0.192
 AA+ATa 71 29 (40.8) 42 0.049 1.829 (0.998–3.35)
rs9024   Cardiotoxicity    
 GG 123 2 (1.6) 121   1.00 (reference)
 GA 69 7 (10.1) 62 0.020 6.831 (1.378–33.866)
 AA 14 2 (14.3) 12 0.052 10.083 (1.301–78.151)
 GA+AAa 83 9 (10.8) 74 0.010 7.358 (1.547–34.989)
  1. Italic values indicate statistical significance
  2. aThe dominant model